Home › Castration-Resistant Prostatic Cancer › Pennsylvania
Pag-aaral pangklinika para sa Castration-Resistant Prostatic Cancer sa Pennsylvania
5 pag-aaral para sa Castration-Resistant Prostatic Cancer ang naghahanap ng mga kalahok sa mga site sa Pennsylvania.
Mga Lungsod sa Pennsylvania
Opisyal na teksto ng pag-aaral (English)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Lehigh Valley Hospital, Allentown
- MidLantic Urology, Bala-Cynwyd
- Penn State Milton S. Hershey Medical Center, Hershey
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- MidLantic Urology, Bala-Cynwyd
- Keystone Urology Specialists, Lancaster
- Penn Medicine Abramson Cancer Center, Philadelphia
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Set 25, 2026 · NCT07164443A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06863272A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Penn State Milton S. Hershey Medical Center, Hershey
- Thomas Jefferson University Honickman Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Kalalakihan · Na-update Ago 13, 2026 · NCT05519449Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.